Evotec SE (EVOTF)
EVOTF
Drug Discovery Platforms
BiotechSign Signal Grade
F
Signal Grade
6.0/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Publications
45
Clinical Activity
8
Short Interest
10
Pipeline Overview
- Therapeutic Focus
- Drug Discovery Platformssrc
Clinical Trial Activity
3
Clinical Trials
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
2 Phase 1
Trial Phase Breakdown
5
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Short Interest
0.45%
Float Shorted
1000.0
Days to Cover
MODERATE
Squeeze Risk
-15.2%
SI Change
DECREASING
Trend
613,426
Shares Short
Short interest: 0.45% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- 4BIO Capital leads €40 Million ($45M) seed financing of Aptadir Therapeutics to advance first-in-class demethylating medicines
- Evotec Announces Chief Scientific Officer Transition
- APTADIR RAISES A €40M ($45M) SEED FINANCING TO ADVANCE FIRST-IN-CLASS DEMETHYLATING MEDICINES
- Secure the Global Drug Discovery Services Report: Capitalize on AI-driven outsourcing and benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Syngene before rivals capture the next revenue wave
- Capitalize on the In Vivo Toxicology Shake-Up: Benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Thermo Fisher Before R&D Shifts Redraw Global Market Share
- Capitalize on the Drug Discovery Outsourcing Shift: Benchmark Charles River, WuXi AppTec, Evotec, Labcorp and Sygnature to Secure R&D ROI and Outsmart the Global Market
- Disrupt Drug Discovery and Secure R&D ROI: Benchmark Fragment-Based Strategies from Astex, Evotec, Charles River, Schrödinger and Vernalis Through 2030
- Capitalize on Compound Management Disruption: Track Brooks Life Sciences, Tecan, Hamilton and Evotec as automation transforms R&D economics and competitive ROI
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial. — ESMO Open 2026 Mar PMID 41687160
- Adjunctive brexpiprazole in patients with major depressive disorder who show minimal or partial response to antidepressant treatment: post hoc analysis of randomized controlled trials. — Int J Neuropsychopharmacol 2025 Oct 1 PMID 41055581
- Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD). — J Affect Disord 2025 Dec 1 PMID 40633778
- Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. — Mol Psychiatry 2024 Aug PMID 38454079
- Design and Evaluation of [(18)F]CHDI-650 as a Positron Emission Tomography Ligand to Image Mutant Huntingtin Aggregates. — J Med Chem 2023 Jan 12 PMID 36548390
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Evotec SE.
Full EVOTF Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.